Sona Nanotech CEO David Regan joined Steve Darling from Proactive to share a major development in the company’s preclinical research. Sona has reported positive results from a required safety study evaluating the potential toxicity and tissue distribution of its proprietary gold nanorods. The study, conducted by CBSET, Inc.—a leading FDA Good Laboratory Practice (GLP) compliant contract research organization—marks a significant step forward in Sona’s pathway toward human clinical trials. The study involved three groups of 20 rats, each administered a different dosage of Sona’s biocompatible gold nanorods through intravenous injection. Researchers assessed safety, tolerability, and organ distribution to determine any adverse effects or toxicity. The results demonstrated a favorable safety profile. Sona’s nanorods showed no evidence of acute or systemic toxicity, and tissue distribution was consistent with established nanoparticle pharmacokinetics. This outcome validates the nanorods’ biocompatibility and supports their use in further therapeutic development. As a GLP-compliant study, the findings meet regulatory standards and will be reported to the U.S. Food and Drug Administration. This data is a prerequisite for an Investigational Device Exemption (IDE), which is necessary to begin human clinical studies in the United States. Regan emphasized that these results are a critical milestone for the company, confirming the safety of its nanotechnology platform and paving the way for expanded preclinical testing. Sona plans to follow FDA guidance closely as it moves forward with its safety program to support a future IDE application and the launch of human trials. The company’s gold nanorods are being developed for potential use in targeted cancer therapies and other advanced medical applications. With this safety data in hand, Sona is advancing toward broader clinical validation and long-term commercialization. #proactiveinvestors #sonananotechinc #cse #sona #otcqb #snanf #CancerTherapy #GoldNanorods #FDAApproval #BiotechNews #Immunotherapy #ClinicalTrials #Nanomedicine #DrugSafety